-
Je něco špatně v tomto záznamu ?
Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile
P. Jansa, S. Heller, M. Svoboda, M. Pad'our, D. Ambrož, V. Dytrych, M. Širanec, T. Kovárník, M. Felšőci, M. Hutyra, A. Linhart, J. Lindner, M. Aschermann,
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články
Grantová podpora
Progres Q38/LF1
Univerzita Karlova v Praze
Free Medical Journals od 2012
PubMed Central od 2012
Europe PubMed Central od 2012
ProQuest Central od 2019-01-01
Open Access Digital Library od 2012-01-01
Open Access Digital Library od 2012-01-01
Health & Medicine (ProQuest) od 2019-01-01
ROAD: Directory of Open Access Scholarly Resources od 2012
Odkazy
PubMed
33182415
DOI
10.3390/jcm9113608
Knihovny.cz E-zdroje
- Publikační typ
- časopisecké články MeSH
Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, p < 0.001), 6 min walking test distance (+54.3 m, p < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, p < 0.001), pulmonary artery mean pressure (-18%, p < 0.001), pulmonary vascular resistance (-32%, p < 0.001), stroke volume (+17%, p = 0.011) and quality of life (+37% in assessment of overall health status by a patient, p < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc21001797
- 003
- CZ-PrNML
- 005
- 20210126092746.0
- 007
- ta
- 008
- 210105s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/jcm9113608 $2 doi
- 035 __
- $a (PubMed)33182415
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Jansa, Pavel $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
- 245 10
- $a Balloon Pulmonary Angioplasty in Patients with Chronic Thromboembolic Pulmonary Hypertension: Impact on Clinical and Hemodynamic Parameters, Quality of Life and Risk Profile. / $c P. Jansa, S. Heller, M. Svoboda, M. Pad'our, D. Ambrož, V. Dytrych, M. Širanec, T. Kovárník, M. Felšőci, M. Hutyra, A. Linhart, J. Lindner, M. Aschermann,
- 520 9_
- $a Balloon pulmonary angioplasty (BPA) is a novel treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are not eligible for pulmonary endarterectomy (PEA) or suffer from persistent pulmonary hypertension after PEA. The aim of this study was to evaluate the real-life efficacy and safety of BPA in a consecutive group of patients who were diagnosed and treated in the national referral center for CTEPH in the Czech Republic. Here we report data from 160 BPA procedures performed in 64 patients. Efficacy analysis was performed in the subgroup of 25 patients who completed BPA series. Significant improvements were observed in New York Heart Association functional class (4% to 79% in I/II, p < 0.001), 6 min walking test distance (+54.3 m, p < 0.001), risk profile (15.8% to 68.5% with presence of 2/3 low risk criteria, p < 0.001), pulmonary artery mean pressure (-18%, p < 0.001), pulmonary vascular resistance (-32%, p < 0.001), stroke volume (+17%, p = 0.011) and quality of life (+37% in assessment of overall health status by a patient, p < 0.001). We observed 1 fatal periprocedural complication (1.6% of all 64 patients) and 19 BPA-related non-fatal complications (11.9% of all 160 interventions) that predominantly included hemoptysis (10.0% of all sessions). Overall survival at 12 months was 94.6%.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Heller, Samuel $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
- 700 1_
- $a Svoboda, Michal $u Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Pad'our, Michal $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
- 700 1_
- $a Ambrož, David $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
- 700 1_
- $a Dytrych, Vladimír $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
- 700 1_
- $a Širanec, Michal $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
- 700 1_
- $a Kovárník, Tomáš $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
- 700 1_
- $a Felšőci, Marián $u Department of Internal Medicine and Cardiology, University Hospital Brno and Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic.
- 700 1_
- $a Hutyra, Martin $u Department of Internal Medicine I-Cardiology, University Hospital, 779 00 Olomouc, Czech Republic.
- 700 1_
- $a Linhart, Aleš $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
- 700 1_
- $a Lindner, Jaroslav $u 2nd Department of Surgery-Department of Cardiovascular Surgery, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
- 700 1_
- $a Aschermann, Michael $u 2nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic.
- 773 0_
- $w MED00195462 $t Journal of clinical medicine $x 2077-0383 $g Roč. 9, č. 11 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33182415 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210126092741 $b ABA008
- 999 __
- $a ind $b bmc $g 1614018 $s 1122081
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 9 $c 11 $e 20201109 $i 2077-0383 $m Journal of clinical medicine $n J Clin Med $x MED00195462
- GRA __
- $a Progres Q38/LF1 $p Univerzita Karlova v Praze
- LZP __
- $a Pubmed-20210105